GC
RGLS

Grimes & Company’s Regulus Therapeutics RGLS Stock Holding History

Grimes & Company’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,975
Closed -$17.2K – 394
2024
Q3 		$17.2K Hold
10,975
– – ﹤0.01% 364
2024
Q2 		$19.6K Buy
10,975
+711
+7% +$1.65K ﹤0.01% 346
2024
Q1 		$29.6K Sell
10,264
-156
-1% -$254 ﹤0.01% 341
2023
Q4 		$13.3K Sell
10,420
-127
-1% -$169 ﹤0.01% 329
2023
Q3 		$14.4K Buy
10,547
+184
+2% +$267 ﹤0.01% 307
2023
Q2 		$15.2K Hold
10,363
– – ﹤0.01% 312
2023
Q1 		$8.78K Buy
+10,363
New +$13.7K ﹤0.01% 305
2022
Q2 		– Sell
-8,820
Closed -$26K – 294
2022
Q1 		$26K Buy
8,820
+2,712
+44% +$7.06K ﹤0.01% 298
2021
Q4 		$19K Sell
6,108
-1,059
-15% -$4.71K ﹤0.01% 298
2021
Q3 		$49K Buy
7,167
+841
+13% +$6.16K ﹤0.01% 300
2021
Q2 		$51K Buy
6,326
+227
+4% +$2.53K ﹤0.01% 299
2021
Q1 		$95K Buy
6,099
+648
+12% +$9.59K ﹤0.01% 275
2020
Q4 		$74K Buy
5,451
+3,051
+127% +$22.4K ﹤0.01% 262
2020
Q3 		$12K Buy
2,400
+450
+23% +$2.96K ﹤0.01% 250
2020
Q2 		$13K Buy
+1,950
New +$12.8K ﹤0.01% 247

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grimes & Company's RGLS Position: Q4 2024 in Review

Grimes & Company sold out of Regulus Therapeutics (RGLS) in Q4 2024, closing a stake of 10,975 shares — an estimated $17.2K sold.

Grimes & Company first reported a position in RGLS in Q2 2020 and held it in 15 quarters. The position peaked at $95K in Q1 2021. 69 funds tracked by Wall St. Rank hold RGLS as of Q4 2024.

  • Grimes & Company reported no remaining Regulus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Grimes & Company sold 10,975 Regulus Therapeutics shares in Q4 2024, an estimated $17.2K.
  • Grimes & Company first reported a position in Regulus Therapeutics in Q2 2020 and held it in 15 quarters.
  • Grimes & Company's Regulus Therapeutics position peaked at $95K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2024.

Based on Grimes & Company's 13F filing for Q4 2024, filed 21 Jan 2025.